反式-1-苄基-4-(4-氟苯基)吡咯烷-3-羧酸乙酯 | 874990-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 反式-1-苄基-4-(4-氟苯基)吡咯烷-3-羧酸乙酯
• 英文名称: 1-benzyl-4-(p-fluoro-phenyl)-pyrrolidine-3-carboxylic acid ethyl ester
• 英文别名: Ethyl 1-benzyl-4-(4-fluorophenyl)pyrrolidine-3-carboxylate
• CAS: 874990-58-6
• 化学式: C₂₀H₂₂FNO₂
• 分子量: 327.399
• InChiKey: ABXZOFRXQMFYAS-UHFFFAOYSA-N

物化性质

• 沸点：
  415.0±45.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  反式-1-苄基-4-(4-氟苯基)吡咯烷-3-羧酸乙酯 、 Lithium aluminium hydride 、 水 、 sodium hydroxide 在 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以The crude title product was obtained as a light yellow oil (14.95 g, 86%)的产率得到(3SR,4RS) [1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-methanol
  参考文献：
  名称：

  PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及一种式子为I的化合物，其中A、Ar、R、R2、R3、R4、p和o的定义如规范和声明中所述，或其药物活性盐。本化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、双相情感障碍、焦虑和注意力缺陷多动障碍（ADHD）。

  公开号：

  US20100210659A1

文献信息

• Pyrrolidine derivatives as NK3 receptor antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US08318759B2

  公开（公告）日：2012-11-27

  The present invention relates to a compounds of formula I wherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及式I的化合物，其中A、Ar、R、R2、R3、R4、p和o如规范和权利要求中所定义的，或其药物活性盐。本发明的化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、双相情感障碍、焦虑和注意力缺陷多动障碍（ADHD）。
• US8318759B2
  申请人：——

  公开号：US8318759B2

  公开（公告）日：2012-11-27
• [EN] PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010094667A1

  公开（公告）日：2010-08-26

  The present invention relates to a compounds of formula I wherein A is -NR'-, -S-, -S(O)- or -S(O)2-; R' is hydrogen or lower alkyl; Ar is aryl or is a five or six membered heteroaryl group, containing one or two N-atoms; R is a five or six membered heterocyclic group X1 is N or CH; and X2 is -N(R1)-, -CH2-, -O-, -S-, -S(O)-, or -S(O)2-, R1 is hydrogen, lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl, C(O)-cycloalkyl optionally substituted by lower alkyl; with the proviso that at least one of X1 or X2 contains a heteroatom, or is a five or six membered heteroaryl group, containing one or two N-atoms, which groups are unsubstituted or may be substituted by one or two R1; wherein R1 is lower alkyl or cyano; R2 is lower alkyl substituted by halogen, halogen, cyano or nitro; R3 is halogen; R4 is hydrogen or lower alkyl; o is 1 or 2; in case o is 2, R2 may be the same or different; p is 1 or 2; in case p is 2, R3 may be the same or different; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).